The EASL CPG Implementation Hub supports the practical application of clinical practice guidelines through educational tools, case-based learning, and implementation resources.
Metabolism, Alcohol and Toxicity
Prevalence of steatosis and steatohepatitis in patients undergoing bariatric surgery: A biopsy-based
Metabolism, Alcohol and Toxicity
Prevalence of steatosis and steatohepatitis in patients undergoing bariatric surgery: A biopsy-based
Basic Science
Computational electrophysiology highlights cardiac toxicity risks of Pentoxifylline, a key therapy f
Basic Science
Computational electrophysiology highlights cardiac toxicity risks of Pentoxifylline, a key therapy f
Metabolism, Alcohol and Toxicity
Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients
Metabolism, Alcohol and Toxicity
Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients
Metabolism, Alcohol and Toxicity
MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events
Metabolism, Alcohol and Toxicity
MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events
Metabolism, Alcohol and Toxicity
Higher cut off values of CAP is needed to avoid over diagnosis of steatosis in obese patients
Metabolism, Alcohol and Toxicity
Higher cut off values of CAP is needed to avoid over diagnosis of steatosis in obese patients
Metabolism, Alcohol and Toxicity
Impact of type 2 diabetes on hepatic fibrosis in patients with MASLD
Metabolism, Alcohol and Toxicity
Impact of type 2 diabetes on hepatic fibrosis in patients with MASLD
Basic Science
Modeling metabolic-dysfunction associated steatotic liver disease in juvenile zebrafish: a novel pla
Basic Science
Modeling metabolic-dysfunction associated steatotic liver disease in juvenile zebrafish: a novel pla
Metabolism, Alcohol and Toxicity
Enhancing trial recruitment in MetALD and ALD with LiverPRO to detect fibrosis
Metabolism, Alcohol and Toxicity
Enhancing trial recruitment in MetALD and ALD with LiverPRO to detect fibrosis
Metabolism, Alcohol and Toxicity
Therapeutic potential and safety profiles of resmetirom in the treatment of non-alcoholic steatohepa
Metabolism, Alcohol and Toxicity
Therapeutic potential and safety profiles of resmetirom in the treatment of non-alcoholic steatohepa
Metabolism, Alcohol and Toxicity
Advanced fibrosis affects quality of life and muscle function in patients with metabolic-dysfunction
Metabolism, Alcohol and Toxicity
Advanced fibrosis affects quality of life and muscle function in patients with metabolic-dysfunction
Basic Science
Association of cardiometabolic risk and phenotypic age with the course of metabolic dysfunction-asso
Basic Science
Association of cardiometabolic risk and phenotypic age with the course of metabolic dysfunction-asso
Metabolism, Alcohol and Toxicity
Enhancing detection of significant fibrosis in people living with HIV: revisiting the conventional A
Metabolism, Alcohol and Toxicity
Enhancing detection of significant fibrosis in people living with HIV: revisiting the conventional A
1of 54Go to: